Commercialization strategy & intelligence
The strategy behind what actually wins.
Commercial counsel and market intelligence for medical aesthetics and adjacent life sciences. Built to serve stakeholders across the industry: manufacturers, investors, and practices.
The thesis
Medical aesthetics is not pharma, not consumer healthcare, not luxury retail. It is all three.
It combines the science and regulation of one with the psychology and economics of the others. Most firms specialize in one part of that system. Our founder has led every one of them.
Our founder's story →What Marga does
Two capabilities.
One foundational framework.
Set the direction,
or the market sets it for you.
We help answer the commercial questions that decide where an asset competes and how far it gets. Brought in on a defined question, or retained as standing counsel to a team already in motion.
- Market and category analysis
- Commercial assessment and due diligence
- Portfolio and asset strategy
- Launch, pricing and lifecycle
Not more data.
An insider read on what it means.
Market data tells you what shipped and what it cost. A Marga read tells you whether it will hold, scored the same way every time and interpreted by someone who has made these decisions from inside the industry.
- The Marga Index™, scored and traceable
- Diligence reads on a named asset
- Standing category monitoring
The common thread
Everything runs through the Marga Index™.
Our proprietary framework for reading the market.
Who we work with
Three stakeholders,
three objectives.
Each one comes with an essay that shows the thinking in full, published ungated.
View all insights →Manufacturers
Turn an asset into a franchise.
Shape the product, evidence, positioning, launch and lifecycle as one connected system instead of six sequential handoffs.
Explore manufacturer strategy →Every Injectable Launch Needs a Touch-Up
A launch is a first pass, not a finished result
The discipline is knowing what to refine once the real world talks back.
Read the essay →Investors
See what the market has not priced in.
Test the durability of demand, the credibility of adoption assumptions and the exposures sitting behind an asset or a category.
Explore investor intelligence →Filler Isn't Dying. It's Being Killed by Its Own Worst Results.
Why the market isn't just correcting
The category is not correcting. It is absorbing the reputational cost of its own worst outcomes.
Read the essay →Providers
Build advantage at the point of care.
Positioning, treatment economics, manufacturer leverage and the patient relationships that compound instead of churn.
Explore the provider community →Trust Is the Only Moat Left in Aesthetics
Why the oldest products still win
Every advantage in this category is copyable except the one that took twenty years to earn.
Read the essay →Get started
The decisions that shape the whole path deserve a full view.
Bring the launch, deal, or growth question into focus.
Start a conversation